Related News
Cypriot geneticists market non-invasive Down Syndrome test
Online Edition
CYPRIOT geneticists on Monday announced the marketing worldwide of what they said is the most accurate non-invasive prenatal diagnostic test for the Down Syndrome, a genetic disorder that leads to physical and mental impairment.
The test, marketed under the brand name of Veracity, will spare the inherent dangers of invasive tests to the life of the fetus and the health of the mother, a statement handed out at a press conference in Nicosia said.
Invasive testing for the Down Syndrome is done by taking a blood sample from the fetus during the early stages of pregnancy, a procedure that can lead to injury to the fetus or even miscarriage in 1-2 percent of the cases.
The Veracity test requires only taking a blood sample from the hand of a gestating woman during a routine visit to her doctor after the 10th week of gestation for diagnostic testing in the laboratory for any abnormal indications, the handout added.
The Veracity Test was developed by a team of geneticists from the Cyprus Institute of Neurology and Genetics (CING) under Professor Philippos Patsalis, currently the Health Minister of Cyprus.
Research on the test started in late 2011 by CING. The test is being merchandised by Non-Invasive Prenatal Diagnostic Genetics Ltd, a spin-off company of CING after the conclusion of several blind validation studies.
The test can detect the presence of third copy of chromosomes 21 (Down Syndrome), 18 (Edward Syndrome), 13 (Patau Syndrome), and of monosomy X (Turner Syndrome), as well as the fetus sex.
The presence of these extra copies in the fetus's genome can lead to a delay in physical growth and mild to moderate intellectual disability of people born with the syndromes.
The Veracity developers said that a simple blood analysis, the results of which can be known within 7 to 10 days can show accurately the presence of these abnormalities.
Out of 600 analysed samples, 52 out of 52 samples were correctly classified as high risk for Trisomy 21. In addition to this, 15 out of 16 samples were correctly classified as high risk for Trisomy 18 and 5 out 5 samples were correctly classified as high risk for Trisomy 13.
A detailed scientific announcement on the non-invasive test will be made by world-renowned Cypriot maternal fetal medicine specialist Prof. Kypros Nicolaides, a pioneer in fetal surgery, at an international fetal medicine meeting in Crete next month.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
